|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Deficit | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Advances from related parties | ||||||||||||||||||||
| Common stock payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Preferred stock value | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Common stock, $0.001 par value, 300,000,000 shares authorized; 130,201,179 shares issued at June 30, 2026 and 2025 | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' Deficit | ||||||||||||||||||||
Loading...
